AU2010284018C1 - Antibodies against the ectodomain of ErbB3 and uses thereof - Google Patents

Antibodies against the ectodomain of ErbB3 and uses thereof Download PDF

Info

Publication number
AU2010284018C1
AU2010284018C1 AU2010284018A AU2010284018A AU2010284018C1 AU 2010284018 C1 AU2010284018 C1 AU 2010284018C1 AU 2010284018 A AU2010284018 A AU 2010284018A AU 2010284018 A AU2010284018 A AU 2010284018A AU 2010284018 C1 AU2010284018 C1 AU 2010284018C1
Authority
AU
Australia
Prior art keywords
antibody
erbb3
seq
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010284018A
Other languages
English (en)
Other versions
AU2010284018A1 (en
AU2010284018B2 (en
Inventor
Michael Feldhaus
Ulrik Nielsen
Birgit Schoeberl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010284018(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of AU2010284018A1 publication Critical patent/AU2010284018A1/en
Application granted granted Critical
Publication of AU2010284018B2 publication Critical patent/AU2010284018B2/en
Publication of AU2010284018C1 publication Critical patent/AU2010284018C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010284018A 2009-08-21 2010-08-23 Antibodies against the ectodomain of ErbB3 and uses thereof Ceased AU2010284018C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
US61/235,799 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (3)

Publication Number Publication Date
AU2010284018A1 AU2010284018A1 (en) 2012-03-22
AU2010284018B2 AU2010284018B2 (en) 2014-06-05
AU2010284018C1 true AU2010284018C1 (en) 2015-10-15

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010284018A Ceased AU2010284018C1 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of ErbB3 and uses thereof

Country Status (21)

Country Link
EP (1) EP2467164A2 (https=)
JP (1) JP5752687B2 (https=)
KR (1) KR20120059568A (https=)
CN (1) CN103002912A (https=)
AU (1) AU2010284018C1 (https=)
BR (1) BR112012003809A2 (https=)
CA (1) CA2771744A1 (https=)
CR (1) CR20120108A (https=)
DO (1) DOP2012000044A (https=)
EA (1) EA201200195A1 (https=)
EC (1) ECSP12011740A (https=)
IL (1) IL218097A0 (https=)
IN (1) IN2012DN01518A (https=)
MA (1) MA33582B1 (https=)
MX (1) MX336091B (https=)
NI (1) NI201200027A (https=)
PE (1) PE20121585A1 (https=)
SG (1) SG178509A1 (https=)
TN (1) TN2012000057A1 (https=)
WO (1) WO2011022727A2 (https=)
ZA (1) ZA201201195B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
MX358013B (es) * 2009-11-13 2018-08-01 Amgen Inc Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
MA33892B1 (fr) 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
CA2792327C (en) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CN102884085B (zh) 2010-04-09 2016-08-03 Aveo制药公司 抗erbb3抗体
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
JP6033783B2 (ja) 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
CN105884900A (zh) 2011-04-19 2016-08-24 梅里麦克制药股份有限公司 单特异性和双特异性抗igf-1r和抗erbb3抗体
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
HK1200468A1 (en) 2011-09-30 2015-08-07 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
AU2012335543C1 (en) 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP2817335A1 (en) * 2012-02-22 2014-12-31 U3 Pharma GmbH Combination of hb-egf binding protein and egfr inhibitor
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2015058108A1 (en) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
CN118580366A (zh) 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
US11390686B2 (en) 2017-08-09 2022-07-19 University Of Saskatchewan HER3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
CN116133694B (zh) * 2020-10-14 2026-03-06 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
JP2023550462A (ja) * 2020-11-20 2023-12-01 アクティニウム ファーマシューティカルズ インコーポレイテッド 固形がんの治療のためのｈｅｒ３放射免疫治療薬
AU2022293634A1 (en) * 2021-06-15 2024-01-18 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BURENKOVA, O. et al American Association for Cancer Research Meeting, April 18 2009. Abstract #1243. *

Also Published As

Publication number Publication date
SG178509A1 (en) 2012-04-27
DOP2012000044A (es) 2012-06-30
JP5752687B2 (ja) 2015-07-22
PE20121585A1 (es) 2012-11-29
AU2010284018A1 (en) 2012-03-22
MX336091B (es) 2016-01-08
CR20120108A (es) 2012-06-05
MX2012002172A (es) 2012-05-29
MA33582B1 (fr) 2012-09-01
TN2012000057A1 (en) 2013-09-19
EP2467164A2 (en) 2012-06-27
BR112012003809A2 (pt) 2019-09-24
ECSP12011740A (es) 2013-02-28
JP2013506622A (ja) 2013-02-28
WO2011022727A2 (en) 2011-02-24
CN103002912A (zh) 2013-03-27
WO2011022727A3 (en) 2013-06-27
EA201200195A1 (ru) 2012-12-28
IL218097A0 (en) 2012-04-30
NI201200027A (es) 2013-01-29
CA2771744A1 (en) 2011-02-24
AU2010284018B2 (en) 2014-06-05
ZA201201195B (en) 2015-07-29
IN2012DN01518A (https=) 2015-06-05
KR20120059568A (ko) 2012-06-08

Similar Documents

Publication Publication Date Title
US20240360243A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
AU2010284018C1 (en) Antibodies against the ectodomain of ErbB3 and uses thereof
AU2012279132B2 (en) Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
AU2011248088B2 (en) Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
HK1138771B (en) Antibodies against erbb3 and uses thereof
HK1230066A1 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
HK1187283A (en) Antibodies against erbb3 and uses thereof
HK1230066A (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JAN 2015 .

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JAN 2015

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2015

MK14 Patent ceased section 143(a) (annual fees not paid) or expired